Reuters logo
3 months ago
BRIEF-Bristol-Myers Squibb and Seattle Genetics expand collaboration to evaluate combination of opdivo and adcetris
June 2, 2017 / 10:16 AM / 3 months ago

BRIEF-Bristol-Myers Squibb and Seattle Genetics expand collaboration to evaluate combination of opdivo and adcetris

June 2 (Reuters) - Bristol-myers Squibb Co

* Bristol-Myers Squibb and Seattle Genetics expand clinical collaboration to evaluate combination of opdivo (nivolumab) and adcetris® (brentuximab vedotin) in pivotal phase 3 clinical trial in relapsed hodgkin lymphoma

* Bristol-Myers Squibb Co - ‍pivotal phase 3 trial planned for mid-2017​

* Bristol-Myers - phase 3 trial to evaluate adcetris alone or with opdivo in relapsed/refractory or transplant-ineligible advanced classical hodgkin lymphoma

* Bristol-Myers Squibb- in addition to planned trial, adcetris, opdivo being evaluated as combination therapy in multiple ongoing phase 1/2 clinical trials

* Bristol-Myers Squibb Co -adcetris, opdivo combination being evaluated for older hl patients,relapsed/refractory classical hl for children, adolescents Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below